FINWIRES · TerminalLIVE
FINWIRES

Manappuram Finance Turns to Profit in Fiscal Q4

By

-- Manappuram Finance (NSE:MANAPPURAM, BOM:531213) posted a consolidated attributable net profit of 4.04 billion Indian rupees in the fiscal fourth quarter ended March 31 against a consolidated loss of 1.91 billion rupees a year ago.

Earnings per share stood at 4.76 rupees compared with a loss per share of 2.40 rupees a year earlier, according to a filing to the stock exchanges on Monday by the financial services provider.

Revenue from operations in fiscal Q4 increased year on year to 26.1 billion rupees from 23.6 billion rupees a year earlier.

The company's board recommended an interim dividend of 0.50 rupees per share for the fiscal year ended March 31, which will be paid to shareholders on record as of May 11.

Related Articles

Mining & Metals

Shopify Q1 Revenue US3,170M

$SHOP.TO
Mining & Metals

Sprott Physical Copper Trust Updates US$500 Million At-the-Market Equity Program

Sprott Asset Management has updated its at-the-market equity program to issue up to US$500 million of units on behalf of Sprott Physical Copper Trust (COP-UN.TO, COP-U.TO), the company said late on Monday.The update was made in connection with the listing of the units of the trust on the New York Stock Exchange Arca.The trust was created to invest and hold substantially all of Sprott Asset Management's assets in physical copper metal. Sprott Asset Management is a subsidiary of Sprott Inc. (SII.TO).Sales of units through U.S. and Canada agents will be made through "at the market" issuances on the NYSE and the Toronto Stock Exchange at the prevailing market price at the time of sale.Proceeds from the ATM program will be used to acquire physical copper metal in accordance with the trust's objective and subject to investment and operating restrictions.Distributions under the ATM programs in Canada and the U.S. will now be completed in accordance with the terms of an amended and restated sales agreement among U.S. and Canada agents, Sprott Asset Management and the trust.

$COP-U.TO$COP-UN.TO$SII.TO
Research

Wedbush Initiates Sionna Therapeutics at Outperform With $53 Price Target

Sionna Therapeutics (SION) has an average rating of buy and mean price target of $50.60, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$SION